Summit Therapeutics $SMMT has crushed high expectations for its Duchenne muscular dystrophy drug, reporting today that their therapy completely failed a key trial. Execs at the biotech say they’re now dumping the drug — the focus of an $842 million deal with Sarepta — and prepping a restructuring needed to survive the setback.
The 48-week Phase II trial failed at the primary as well as secondary level, researchers say, leaving nothing worthwhile to pursue in a late-stage study. The entire program is being scrapped now, and the news hit shares hard, with the stock plunging 77%.
Sarepta $SRPT had partnered with Summit on the drug — providing $40 million upfront with R&D support — looking to move beyond its fragile success with their experimental Exondys51. That drug was approved for DMD after a bruising internal dispute at the FDA — but on the market with a label that says there’s still no solid evidence of its efficacy.
The Oxford-based Summit saw its shares surge back at the beginning of the year on positive preliminary results, with their utrophin modulator ezutromid demonstrating a 23% decrease in myosin. But biomarker activity is no stand-in for a disease like DMD.
Sarepta too has relied heavily on biomarker data for its therapies, bagging a notable but very early success with a gene therapy for the disease.
Summt is now planning some painful cost cutting, which likely means a reduction in headcount.
“While we believe utrophin modulation could still have a place in the treatment of DMD, it is clear that ezutromid is not providing a benefit for patients,” said CEO Glyn Edwards. “We therefore feel that our resources are better focused on the development of our promising pipeline of new mechanism antibiotics.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.Free Subscription